Mefenorex
From Wikipedia, the free encyclopedia
Mefenorex
|
|
Systematic (IUPAC) name | |
N-(3-chloropropyl)-1-phenylpropan-2-amine | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C12H18ClN |
Mol. mass | 211.731 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.[1][2]
Mefenorex produces amphetamine as a metabolite,[3] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.[4]
[edit] References
- ^ Vincendeau MJ. A new regulator of appetite: mefenorex. (French). Bordeaux Medical. 1970 Jul-Aug;3(7):1951-3.
- ^ Beyer G, Huth K, Muller GM, Niemoller H, Raisp I, Vorberg G. The treatment of obesity with the appetite curbing agent Mefenorex. (German). Die Medizinische Welt. 1980 Feb;31(8):306-9.
- ^ Rendic S, Slavica M, Medic-Saric M. Urinary excretion and metabolism of orally administered mefenorex. European Journal of Drug Metabolism and Pharmacokinetics. 1994 Apr-Jun;19(2):107-17.
- ^ Engel J, Kristen G, Schaefer A, von Schlichtegroll A. Mefenorex (Rondimen). Drug and Alcohol Dependence. 1986 Jun;17(2-3):229-34.